Immunohistochemical Expression of Cyclin D1 in Invasive Breast Carcinoma
DOI:
https://doi.org/10.51985/JBUMDC2024384Keywords:
Breast carcinoma; cyclin D1; ER; PR; HER2; KI67Abstract
Objective: This study was conducted to determine the immunohistochemical expression of cyclin D1 in invasive breast carcinoma and its association with already established prognostic parameters like estrogen receptor (ER), progesterone receptor (PR), HER2/Neu, and Ki67 status.
Study Design & Setting: Cross sectional Observational. Department of Pathology, Armed Forces Institute of Pathology, Rawalpindi
Methodology: The study included 350 cases of invasive breast cancer diagnosed between January 2023 and December 2023. Data collected included patient age, histological subtype, molecular subtypes, tumor size, and the presence of estrogen (ER) and progesterone (PR) receptors, as well as HER2/Neu and Ki67 status. Patients who had undergone chemotherapy, received radiation to the breasts, or experienced relapse were excluded from the study. Immunohistochemistry was conducted using a Cyclin D1 antibody to assess Cyclin D1 expression in tissue samples. The expression levels were categorized as negative, weak, moderate, strong staining in tumor cells. Data analysis was performed using SPSS 29.0, and statistical comparisons were made between Cyclin D1 staining and ER, PR, HER2/Neu, and Ki67 status.
Results: Cyclin D1 moderate to strong staining was seen in 173/352 (49.14%) cases of invasive BC. Cyclin D1 expression was slightly statistically significantly associated with ER (x2 = 7.78, P value <0.051) and Ki67 positivity (÷2 = 7.27, P value <0.064).
Conclusion: Cyclin D1 has the potential to serve as a prognostic marker. Incorporating it into the routine IHC workup for breast cancer could enhance patient management, especially with the development of new targeted therapies that inhibit the Cyclin D-CDK4/6 axis.
References
Leone JP, Graham N, Tolaney SM, Leone BA, Freedman RA,
Hassett MJ, et al. Estimating long-term mortality in women
with hormone receptor-positive breast cancer: The
‘ESTIMATE’tool. European Journal of Cancer. 2022;173:20-
Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS,
Rees CA, et al. Molecular portraits of human breast tumours.
nature. 2000;406(6797):747-52.
Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast
cancer research and treatment. 1998;52:1-15.
Tsang JY, Gary MT. Molecular classification of breast cancer.
Advances in anatomic pathology. 2020;27(1):27-35.
Group EBCTC. Effects of chemotherapy and hormonal therapy
for early breast cancer on recurrence and 15-year survival:
an overview of the randomised trials. The Lancet.
;365(9472):1687-717.
Shah AU, Mahjabeen I, Kayani MA. Genetic polymorphisms
in cell cycle regulatory genes CCND1 and CDK4 are associated
with susceptibility to breast cancer. Journal of buon.
;20(4):985-93.
Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW,
Nicholson RI, et al. Overexpression of cyclin D1 messenger
RNA predicts for poor prognosis in estrogen receptor-positive
breast cancer. Clin Cancer Res. 1999;5(8):2069-76.
Velasco-Velázquez MA, Li Z, Casimiro M, Loro E, Homsi
N, Pestell RG. Examining the role of cyclin D1 in breast
cancer. Future Oncology. 2011;7(6):753-65.
Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J,
Bernards R, Michalides RJ. CDK-independent activation of
estrogen receptor by cyclin D1. Cell. 1997;88(3):405-15.
Beg S, Haider G, Khan E, Shahid A, Memon P, Rahul R, et
al. Diversity Of Histological Variants Of Breast Cancer: A
Tertiary Care Hospital Experience In Karachi, Pakistan. Pakistan
Armed Forces Medical Journal. 2020;70(4):1119-24.
Ravikumar G, Ananthamurthy A. Cyclin D1 expression in
ductal carcinoma of the breast and its correlation with other
prognostic parameters. J Cancer Res Ther. 2014;10(3):671-
Qureshi A, Pervez S. Allred scoring for ER reporting and it's
impact in clearly distinguishing ER negative from ER positive
breast cancers. Journal Pakistan Medical Association.
;60(5):350
Collins LC, Botero ML, Schnitt SJ. Bimodal frequency
distribution of estrogen receptor immunohistochemical staining
results in breast cancer: an analysis of 825 cases. Am J Clin
Pathol. 2005;123(1):16-20.
Krishnamurti U, Silverman JF. HER2 in breast cancer: a
review and update. Adv Anat Pathol. 2014;21(2):100-7.
Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O. Ki-67
expression in axillary lymph node metastases in breast cancer
is prognostically significant. Hum Pathol. 2013;44(1):39-46.
Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C,
et al. Amplification and overexpression of cyclin D1 in breast
cancer detected by immunohistochemical staining. Cancer
Res. 1994;54(7):1812-7.
Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY. Expression of c-erbB2, cyclin D1 and estrogen receptor and their
clinical implications in the invasive ductal carcinoma of the
breast. Jpn J Clin Oncol. 2007;37(9):708-14.
Sarkar S, Kanoi A, Bain J, Gayen R, Das KN. Correlation
between cyclin D1 expression and standard clinicopathological
variables in invasive breast cancer in Eastern India. South
Asian Journal of Cancer. 2015;4(04):155-9.
Van Diest PJ, Michalides R, Jannink L, Van der Valk P, Peterse
HL, De Jong JS, et al. Cyclin D1 expression in invasive breast
cancer. Correlations and prognostic value. The American
journal of pathology. 1997;150(2):705.
Lengare PV, Khandeparkar SGS, Joshi AR, Gogate BP, Solanke
SG, Gore SH. Immunohistochemical expression of cyclin D1
in invasive breast carcinoma and its correlation with clinicopathological parameters. Indian J Pathol Microbiol.
;63(3):376-81.
Mohammadizadeh F, Hani M, Ranaee M, Bagheri M. Role
of cyclin D1 in breast carcinoma. Journal of research in
medical sciences: the official journal of Isfahan University
of Medical Sciences. 2013;18(12):1021.
Peurala E, Koivunen P, Haapasaari K-M, Bloigu R, JukkolaVuorinen A. The prognostic significance and value of cyclin
D1, CDK4 and p16 in human breast cancer. Breast Cancer
Res. 2013;15(1):1-10.
Kucukzeybek BB, Bayoglu IV, Kucukzeybek Y, Alacacioglu
A, Yigit S, Sari AA, et al. The prognostic significance of
cyclin D1 expression in patients with triple-negative breast
cancer. J BUON. 2017;22(4):947-52.
Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition
in breast cancer: current practice and future directions. Ther
Adv Med Oncol. 2018;10:1758835918786451.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Tabish Hassan, Nadeem Zafar, Akhter Ali Bajwa, Rabia Ahmed, Muhammad Umair, Mubina Qayyum
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
